JUN 2 3 2009

PTO/SB/08 (09-06) Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARIMENT OF COMMENT OF CO INFORMATION DISCLOSURE **Application Number** 10/567,328 STATEMENT BY APPRLICANT. Filing Date 8/6/2004 **First Named Inventor** Makoto SAWADA Date Submitted: JUN 23 2009 **Art Unit** 1649 (use as many sheets as necessary) **Examiner Name** Kimberly BALLARD Sheet 1 2 of **Attorney Docket Number** 084335-0201

U.S. PATENT DOCUMENTS					
Examin er Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

			FOREIGN PATENT DOCUMENTS					
Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4-</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т6			
F1	WO 03/009881 A2	02/06/2003	Imary Therangutics Inc	i iga.co.r.ppca.	<b>-</b>			
F2	WO 03/020751 A2	03/13/2003	King's College London					
F	No. <sup>1</sup>	No. <sup>1</sup> Country Code <sup>3</sup> Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )  1 WO 03/009881 A2	No. <sup>1</sup> Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )  MM-DD-YYYY  VO 03/009881 A2  02/06/2003	Country Code <sup>3</sup> Number <sup>4-</sup> Kind Code <sup>5</sup> (if known)  MM-DD-YYYY Applicant of Cited Documents  WO 03/009881 A2 02/06/2003 Imarx Therapeutics, Inc.	Country Code <sup>3</sup> Number <sup>4-</sup> Kind Code <sup>5</sup> ( <i>if known</i> )  MM-DD-YYYY  Applicant of Cited Documents  Name of Patentee or Applicant of Cited Documents  Passages or Relevant Figures Appear  Imarx Therapeutics, Inc.			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	F3	Supplementary European Search Report mailed April 8, 2009, in European Patent Application EP 06783020), 4 pages.	
	F4	BODER et al., "Yeast surface display for screening combinatorial polypeptide libraries," Nature Biotechnology, June 1, 1997, 15:553-557.	
	F5	EGLETON et al., "Transport of Opioid Peptides into the Central Nervous System," Journal of Pharmaceutical Sciences, November 1998, 87(11):1433-1439.	
	F6	KIM et al., "Human neural stem cells genetically modified for brain repair in neurological disorders," Neuropathology: Official Journal of the Japanese Society of Neuropathology, September 2004, 24(3):159-171.	
	F7	KONDO et al., "Yeast cell-surface display-applications of molecular display," Applied Microbiology and Biotechnology, March 1, 2004, 64(1):28-40.	
	F8	LAAKKONEN et al., "A tumor-homing peptide with a targeting specificity related to lymphatic vessels," Nature Medicine, June 10, 2002, 8(7):751-755.	
	F9	LAAKKONEN et al., "Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells," Proc. Natl. Acad. Sci., June 22, 2004, 101(25):9381-9386.	

Examiner	Date
Signature	
Signature	Considered
*EVANINED. In	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for for	m 1449/PTO		Complete if Known		
	INFORMATION I	DISCLOSURE	Application	on Number	10/567,328	
	STATEMENT BY	APPLICANT	Filing Dat	te	8/6/2004	
Dat	Date Submitted: JUN 23 2009			ned Inventor	Makoto SAWADA	<del></del>
Date Submitted. OCH 2 0 Z003			Art Unit		1649	<u> </u>
(	(use as many sheets as necessary)			Name	Kimberly BALLARD	
Sheet	2	of 2	Attorney [	Docket Number	084335-0201	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issequences.  number(s), publisher, city and/or country where published.		T		
	F10	MAKAR et al., "Brain-derived neurotrophic factor (BDNF) gene delivery into the CNS using bone marrow cells as vehicles in mice," Neuroscience Letters, February 17, 2004, 356:215-219.			
	F11	PIWKO et al., "Localization and Pharmacological Characterization of Somatostatin Recognition Sites in the Human Cerebellum," Neuropharmacology, June 1996, 35(6):713-723.			

Examiner	Date
Signature	Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.